John VandermostenSenior Biotech Analyst at Zacks
John Vandermosten is currently a senior biotechnology research analyst for Zacks Investment Research where he covers a portfolio of small cap biotechnology names. His background includes 17 years of experience in a variety of investment management and research roles across all market cap ranges and throughout the capital structure. Formerly, John was a research analyst for Singular Research covering the health care space and a consultant with Coker Group, a national healthcare services firm providing financial advisory, investment banking, healthcare IT and other services to hospitals and other health care organizations. John also worked at the Teacher Retirement System of Texas as investment analyst on the agency’s large cap call overwriting fund. John has an MBA from Texas A&M University, an MA from Tulane University and a BA from San Diego State University. He has also earned the Chartered Financial Analyst (CFA) designation and is a member of the CFA Society of Dallas.